Areteus s.r.o.

The medical center is at the forefront of research in Severe Hypertriglyceridemia (SHTG), focusing on innovative treatments to manage this complex condition. The ongoing study of olezarsen aims to assess its safety and tolerability when administered subcutaneously, offering new hope for patients with elevated triglyceride levels.

• Safety and Tolerability of Olezarsen
• Innovative Subcutaneous Administration

Through this research, the center contributes significantly to the understanding and management of lipid disorders, potentially transforming therapeutic approaches for patients with severe lipid imbalances.

Specializing in Type 2 Diabetes Mellitus, the center is dedicated to advancing treatment options that improve glycemic control. The study of AZD5004 versus placebo over a 26-week period is designed to evaluate its efficacy, safety, and tolerability, providing critical insights into daily oral administration therapies.

• Glycemic Control Enhancement
• Long-term Safety and Efficacy

This research underscores the center's commitment to developing effective diabetes management strategies, enhancing patient outcomes through cutting-edge clinical trials.